Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Armata Pharmaceuticals, Inc. ARMP
$1.45
+$0.17 (11.53%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
49518239.00000000
-
week52high
4.92
-
week52low
0.83
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.53838600
-
EPS
-1.05000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 22 мар 2021 г. |
| H.C. Wainwright | Buy | 15 мая 2020 г. | |
| H.C. Wainwright | Buy | 20 мар 2020 г. | |
| Maxim Group | Buy | 06 февр 2020 г. | |
| Ladenburg Thalmann | Buy | 19 июн 2019 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Peterson Todd C. | A | 33000 | 33000 | 13 апр 2022 г. |
| Patrick Todd | A | 33000 | 33000 | 13 апр 2022 г. |
| Schlesinger Sarah J. | A | 33000 | 33000 | 13 апр 2022 г. |
| Kramer Robin | A | 33000 | 33000 | 13 апр 2022 г. |
| Odysseas Kostas D | A | 33000 | 33000 | 13 апр 2022 г. |
| PATTI JOSEPH M | A | 33000 | 33000 | 13 апр 2022 г. |
| Morris Duane Alfred | A | 41000 | 41000 | 13 апр 2022 г. |
| Haimovitz Jules | A | 33000 | 33000 | 13 апр 2022 г. |
| Varnum Brian | A | 240000 | 240000 | 13 апр 2022 г. |
| Innoviva, Inc. | A | 2692604 | 0 | 31 мар 2022 г. |
Новостная лента
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 19:02
Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.30 per share a year ago.
After Plunging 35.3% in 4 Weeks, Here's Why the Trend Might Reverse for Armata Pharmaceuticals, Inc. (ARMP)
Zacks Investment Research
28 ноя 2022 г. в 11:17
Armata Pharmaceuticals, Inc. (ARMP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
PRNewsWire
28 ноя 2022 г. в 08:00
MARINA DEL REY, Calif. , Nov. 28, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the company will participate in the H.C.
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research
09 ноя 2022 г. в 20:19
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 11.11% and 3.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research
11 авг 2022 г. в 18:49
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 0% and 98.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?